SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artículo

FERRES, Marcela; NERVI, Bruno  y  RAMIREZ, Pablo. Profilaxis de citomegalovirus en niños y adultos sometidos a trasplante de órganos sólidos y de precursores hematopoyéticos. Rev. chil. infectol. [online]. 2012, vol.29, suppl.1, pp. 23-28. ISSN 0716-1018.  http://dx.doi.org/10.4067/S0716-10182012000500004.

    1.- Paya C V. Prevention of cytomegalovirus disease in recipients of solid-organ transplants. Clin Infect Dis 2001; 32: 596-603. [ Links ]

    2.- Stagno S, Dworsky M E, Torres J, Mesa T, Hirsh T. Prevalence and importance of congenital cytomegalovirus infection in three different populations. J Pediatr 1982; 101: 897-900. [ Links ]

    3.- Vial P, Torres-Pereyra J, Stagno S, González F, Donoso E, Alford C A, et al. Estudio serológico para CMV, HSV, rubéola, hepatitis B y Toxoplasma gondif en dos poblaciones de gestantes en Santiago, Chile. Bol Oficina Sanit Panam 1985; 99: 528-38. [ Links ]

    4.- Abarca K, Vial P A, Zamorano J, Paris C, Ferres M, Villarroel L, et al. Seroprevalence of cytomegalovirus and Toxoplasma gondif in healthy subjects under 30 years old in Santiago, Chile. Rev Med Chile 1997; 125: 531-8. [ Links ]

    5.- Cannon M J, Schmid D S, Hyde T B. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 2010; 20: 202-13. [ Links ]

    6.- Rubin R H, Kemmerly S A, Conti D, Doran M, Murray B M, Neylan J F, et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transpl Infect Dis 2000; 2: 112-7. [ Links ]

    7.- Paya C V, Razonable R R. Transplant Infections. 2nd edition ed; 2003. [ Links ]

    8.- Boeckh M. Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: Prevention and therapy. Transpl Infect Dis 1999; 1: 165-78. [ Links ]

    9.- Ljungman P. CMV infections after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 42 Suppl 1: S70-S2. [ Links ]

    10.- Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4: S78-86. [ Links ]

    11.- Leather H L, Wingard J R. Infections following hematopoietic stem cell transplantation. Infect Dis Clin North Am 2001; 15: 483-520. [ Links ]

    12.- Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am 2011; 25: 151-69. [ Links ]

    13.- Nichols W G, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185: 273-82. [ Links ]

    14.- Hodson E M, Craig J C, Strippoli G F, Webster AC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane database of systematic reviews (Online) 2008: CD003774. [ Links ]

    15.- Peggs K S, Preiser W, Kottaridis P D, McKeag N, Brink N S, Tedder R S, et al. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation. Br J Haematol 2000; 111: 782-90. [ Links ]

    16.- Krause H, Hebart H, Jahn G, Muller C A, Einsele H. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant 1997; 19: 1111-6. [ Links ]

    17.- Zaia J A, Gallez-Hawkins G M, Tegtmeier B R, Ter Veer A, Li X, Niland J C, et al. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J Infect Dis 1997; 176: 782-5. [ Links ]

    18.- Paya C, Humar A, Domínguez E, Washburn K, Blumberg E, Alexander B, et al. Eficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-20. [ Links ]

    19.- Kotton C N, Kumar D, Caliendo A M, Asberg A, Chou S, Snydman D R, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-95. [ Links ]

    20.- McGillicuddy J W, Weimert N A, Taber D J, Turner A, Mitchell L A, Wray D W, et al. Can preemptive cytomegalovirus monitoring be as effective as universal prophylaxis when implemented as the standard of care in patients at moderate risk? Transplantation 2010; 89: 1218-23. [ Links ]

    21.- Preiksaitis J K, Brennan D C, Fishman J, Allen U. Canadian Society of Transplantation consensus workshop on cytomegalovirus management in solid organ transplantation inal report. Am J Transplant 2005; 5: 218-27. [ Links ]

    22.- Ljungman P, Larsson K, Kumlien G, Aschan J, Barkholt L, Gustafsson-Jernberg A, et al. Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors. Scand J Infect Dis 2002; 34: 347-50. [ Links ]

    23.- Nichols W G, Price T H, Gooley T, Corey L, Boeckh M. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003; 101: 4195-200. [ Links ]

    24.- Bowden R A, Slichter S J, Sayers M, Weisdorf D, Cays M, Schoch G, et al. A comparison of iltered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86: 3598-603. [ Links ]

    25.- Razonable R R, Paya C V, Smith T F. Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients. J Clin Microbiol 2002; 40: 746-52. [ Links ]

    26.- Palladino M, Laurenti L, Chiusolo P, Piccioni P, Innocenti I, Tarnani M, et al. Low-dose valganciclovir as preemptive therapy for cytomegalovirus infection occurring in allogeneic stem cell transplant recipients. Acta Haematol 2010; 123: 230-4. [ Links ]

    27.- van der Heiden P L, Kalpoe J S, Barge R M, Willemze R, Kroes A C, Schippers E F. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant 2006; 37: 693-8. [ Links ]

    28.- Raymund MFR. In: Meet-the-Professor: CMV management in immunocompromised patients. IDSA 48th Vancouver; 2010. [ Links ]